Life Scientist > Life Sciences

'Self-replicating' bogeyman strikes at nanotech researchers

07 February, 2005 by Graeme O'Neill

'Nanotechnobabble' is already making life difficult for bio-nanotechnology researchers, with technophobes warning of the risk of uncontrollable, self-replicating nanobots overrunning the world, the Lorne Conference on Protein Structure and Function at Phillip Island, in Victoria, heard today.


Plasvacc buys US vet plasma company

07 February, 2005 by Melissa Trudinger

Queensland veterinary blood plasma company PlasVacc has purchased US plasma company Veterinary Dynamics Inc (VDI).


Stem Cell Sciences receives DTI funding

01 February, 2005 by Melissa Trudinger

A consortium led by Stem Cell Sciences' UK centre has been awarded £1.2 million by the UK Department of Trade and Industry (DTI) to fund a program in drug discovery for regenerative medicine.


Synthetic blood vessels in the offing

21 January, 2005 by Graeme O'Neill

The fact that blood's not only thicker than water, but biologically "sticky", creates problems for cardiovascular surgeons replacing blocked coronary arteries.


Plants, animals, not to be covered by innovation patent

01 December, 2004 by Renate Krelle

The federal government has accepted the recommendations of the Advisory Council on Intellectual Property, maintaining the status quo and continuing to exclude the patenting of plants, animals and the biological processes involved in their generation.


Senator warns on stem cell complacency

26 November, 2004 by Melissa Trudinger

Australian Democrats senator Natasha Stott Despoja has warned Australian stem cell researchers not to be complacent as the review on the 2002 cloning and stem cell legislation draws close.


Stem cell debate set to reopen

26 November, 2004 by Melissa Trudinger

Stem cell researchers are gearing up for the reopening of the stem cell debate next year, when federal government legislation covering the use of spare IVF embryos and the moratorium on therapeutic cloning -- otherwise known as nuclear transfer -- comes up for review.


Microbes vs Minoans: environmental biotech gets tough

25 November, 2004 by Iain Scott

Western society is wasteful of its water, a Sydney meeting heard today -- and the Minoans are to blame.


Biodiem licenses flu vaccine

24 November, 2004 by Melissa Trudinger

BioDiem (ASX: BDM) has licensed its cell-culture production influenza vaccine to Dutch group Nobilon, part of Akzo Nobel's pharma group, for USD$8 million including milestone payments.


UQ spinout to develop brain's own analgesic

23 November, 2004 by Graeme O'Neill

In the New Age of "natural" remedies, there's no more natural a remedy for pain than the brain's native analgesic, endomorphin. It's an easy synthesis: a simple pentapeptide, that would be an instant winner for headaches and chronic neuropathic pain, if only someone could bottle it in tablet form.


Aust govt backflip on stem cell support

23 November, 2004 by Melissa Trudinger

The Australian government has quietly reversed its position on therapeutic cloning and embryonic stem cell research by co-sponsoring the Costa Rica-US led proposal to the UN to ban all forms of human cloning including so-called therapeutic cloning and the experimental use of embryonic stem cells.


NHMRC grants stem cell licence to Sydney group

17 November, 2004 by Melissa Trudinger

IVFAustralia and the Diabetes Transport Unit (DTU) at the Prince of Wales Hospital in Sydney have been granted a licence by the NHMRC to create up to six new human embryonic stem cell (hESC) lines from spare IVF embryos.


Australian group offers open access to new ES cell line

15 November, 2004 by Melissa Trudinger

The first of six human embryonic stem cell (hESC) lines to be developed by Stem Cell Sciences, Melbourne IVF and the Australian Stem Cell Centre has been produced and will be made available to researchers around the world unfettered by commercial restrictions.


Cygenics to collaborate with Peter Mac on T cell trials

10 November, 2004 by Melissa Trudinger

Cygenics (ASX: CYN) subsidiary Cytomatrix has entered into a collaboration with Cell Therapies, the commercial arm of the Peter MacCallum Cancer Centre's Centre for Blood Cell Therapies, to test the company's T cell production technology in human clinical trials.


AusBiotech 2004: Stem cell pioneer tells why all's well in Wales

05 November, 2004 by Melissa Trudinger

One of the leading lights of international stem cell research will be in Australia next week, as a de facto ambassador for Wales as well as to discuss his research.


  • All content Copyright © 2025 Westwick-Farrow Pty Ltd